APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neurokinin Receptor Antagonists for Vasomotor Symptoms

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

28 December 2025177 pages

Choose your research edition.

Industry ResearchNeurokinin Receptor Antagonists for Vasomotor Symptoms Industry Research Report 2026107 pages · $2,950 USDIndustry Growth & TrendsGlobal Neurokinin Receptor Antagonists for Vasomotor Symptoms Industry Growth and Trends Forecast to 203278 pages · $3,450 USDMarket StructureGlobal Neurokinin Receptor Antagonists for Vasomotor Symptoms Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032177 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Neurokinin Receptor Antagonists for Vasomotor Symptoms market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Neurokinin Receptor Antagonists for Vasomotor Symptoms is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Neurokinin Receptor Antagonists for Vasomotor Symptoms is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neurokinin Receptor Antagonists for Vasomotor Symptoms is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Neurokinin Receptor Antagonists for Vasomotor Symptoms is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Neurokinin Receptor Antagonists for Vasomotor Symptoms include Astellas Pharma and Bayer among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Neurokinin Receptor Antagonists for Vasomotor Symptoms market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Neurokinin Receptor Antagonists for Vasomotor Symptoms and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Neurokinin Receptor Antagonists for Vasomotor Symptoms sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Neurokinin Receptor Antagonists for Vasomotor Symptoms market size, projected growth trends, production technologies, key applications, and end-use industries.

Neurokinin Receptor Antagonists for Vasomotor Symptoms Segment by Company

Astellas Pharma

Bayer

Neurokinin Receptor Antagonists for Vasomotor Symptoms Segment by Type

Fezolinetant

Elinzanetant

Neurokinin Receptor Antagonists for Vasomotor Symptoms Segment by Application

Hospital and Clinic

Pharmacy

Other

Neurokinin Receptor Antagonists for Vasomotor Symptoms Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neurokinin Receptor Antagonists for Vasomotor Symptoms market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neurokinin Receptor Antagonists for Vasomotor Symptoms and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neurokinin Receptor Antagonists for Vasomotor Symptoms.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Neurokinin Receptor Antagonists for Vasomotor Symptoms market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Neurokinin Receptor Antagonists for Vasomotor Symptoms manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Neurokinin Receptor Antagonists for Vasomotor Symptoms in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Neurokinin Receptor Antagonists for Vasomotor Symptoms in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Neurokinin Receptor Antagonists for Vasomotor Symptoms Industry Trends Table 2. Neurokinin Receptor Antagonists for Vasomotor Symptoms Industry Drivers Table 3. Neurokinin Receptor Antagonists for Vasomotor Symptoms Industry Opportunities and Challenges Table 4. Neurokinin Receptor Antagonists for Vasomotor Symptoms Industry Restraints Table 5. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Manufacturers Table 9. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Manufacturers, Product Type & Application Table 13. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Fezolinetant Table 17. Major Manufacturers of Elinzanetant Table 18. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type (2021-2026) & (K Units) Table 20. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type (2027-2032) & (K Units) Table 21. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Type (2021-2026) Table 22. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Type (2027-2032) Table 23. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Type (2021-2026) & (K Units) Table 25. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Type (2027-2032) & (K Units) Table 26. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share by Type (2021-2026) Table 27. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Hospital and Clinic Table 29. Major Manufacturers of Pharmacy Table 30. Major Manufacturers of Other Table 31. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application (2021-2026) & (K Units) Table 33. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application (2027-2032) & (K Units) Table 34. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Application (2021-2026) Table 35. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Application (2027-2032) Table 36. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Application (2021-2026) & (K Units) Table 38. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Application (2027-2032) & (K Units) Table 39. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share by Application (2021-2026) Table 40. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share by Application (2027-2032) Table 41. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Region (2021-2026) & (K Units) Table 43. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Region (2021-2026) Table 44. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Forecasted by Region (2027-2032) & (K Units) Table 45. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 47. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2021-2026) & (K Units) Table 48. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2027-2032) & (K Units) Table 49. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2021-2026) & (K Units) Table 51. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2027-2032) & (K Units) Table 52. Asia Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Asia Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2021-2026) & (K Units) Table 54. Asia Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2027-2032) & (K Units) Table 55. South America, Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. South America, Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2021-2026) & (K Units) Table 57. South America, Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2027-2032) & (K Units) Table 58. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share by Region (2021-2026) Table 62. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share by Region (2027-2032) Table 63. Astellas Pharma Company Information Table 64. Astellas Pharma Business Overview Table 65. Astellas Pharma Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Astellas Pharma Neurokinin Receptor Antagonists for Vasomotor Symptoms Product Portfolio Table 67. Astellas Pharma Recent Development Table 68. Bayer Company Information Table 69. Bayer Business Overview Table 70. Bayer Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Bayer Neurokinin Receptor Antagonists for Vasomotor Symptoms Product Portfolio Table 72. Bayer Recent Development Table 73. Key Raw Materials Table 74. Raw Materials Key Suppliers Table 75. Neurokinin Receptor Antagonists for Vasomotor Symptoms Distributors List Table 76. Neurokinin Receptor Antagonists for Vasomotor Symptoms Customers List Table 77. Research Programs/Design for This Report Table 78. Authors List of This Report Table 79. Secondary Sources Table 80. Primary Sources List of Figures Figure 1. Neurokinin Receptor Antagonists for Vasomotor Symptoms Product Image Figure 2. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size (2021-2032) & (US$ Million) Figure 4. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales (2021-2032) & (K Units) Figure 5. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Neurokinin Receptor Antagonists for Vasomotor Symptoms Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Fezolinetant Image Figure 9. Elinzanetant Image Figure 10. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Type (2021-2032) Figure 13. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share by Type (2021-2032) Figure 16. Hospital and Clinic Image Figure 17. Pharmacy Image Figure 18. Other Image Figure 19. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Application (2021-2032) Figure 22. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share by Application (2021-2032) Figure 25. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales and Growth Rate (2021-2032) & (K Units) Figure 26. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Country (2021-2032) Figure 27. U.S. Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Canada Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Mexico Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Country (2021-2032) Figure 32. Germany Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales and Growth Rate (2021-2032) & (K Units) Figure 33. France Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales and Growth Rate (2021-2032) & (K Units) Figure 34. U.K. Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Italy Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Netherlands Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Country (2021-2032) Figure 39. China Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Japan Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales and Growth Rate (2021-2032) & (K Units) Figure 41. South Korea Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Southeast Asia Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales and Growth Rate (2021-2032) & (K Units) Figure 43. India Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Australia Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Country (2021-2032) Figure 47. Brazil Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Saudi Arabia Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Turkey Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Argentina Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales and Growth Rate (2021-2032) & (K Units) Figure 52. UAE Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Egypt Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Chile Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue (2021-2032) & (US$ Million) Figure 58. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue (2021-2032) & (US$ Million) Figure 60. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Neurokinin Receptor Antagonists for Vasomotor Symptoms Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Neurokinin Receptor Antagonists for Vasomotor Symptoms Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Fezolinetant
  • Elinzanetant
Applications
  • Hospital and Clinic
  • Pharmacy
  • Other
Companies covered
  • Astellas Pharma
  • Bayer

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Dynamics
  1. 2.1 Neurokinin Receptor Antagonists for Vasomotor Symptoms Industry Trends
  2. 2.2 Neurokinin Receptor Antagonists for Vasomotor Symptoms Industry Drivers
  3. 2.3 Neurokinin Receptor Antagonists for Vasomotor Symptoms Industry Opportunities and Challenges
  4. 2.4 Neurokinin Receptor Antagonists for Vasomotor Symptoms Industry Restraints
3 Neurokinin Receptor Antagonists for Vasomotor Symptoms Market by Manufacturers
  1. 3.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Manufacturers (2021-2026)
  3. 3.3 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Manufacturers, Product Type & Application
  7. 3.7 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Neurokinin Receptor Antagonists for Vasomotor Symptoms Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Neurokinin Receptor Antagonists for Vasomotor Symptoms Tier 1, Tier 2, and Tier 3
4 Neurokinin Receptor Antagonists for Vasomotor Symptoms Market by Type
  1. 4.1 Neurokinin Receptor Antagonists for Vasomotor Symptoms Type Introduction
  2. 4.1.1 Fezolinetant
  3. 4.1.2 Elinzanetant
  4. 4.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type
  5. 4.2.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type (2021-2032)
  7. 4.2.3 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Type (2021-2032)
  8. 4.3 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Type
  9. 4.3.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Type (2021-2032)
  11. 4.3.3 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share by Type (2021-2032)
5 Neurokinin Receptor Antagonists for Vasomotor Symptoms Market by Application
  1. 5.1 Neurokinin Receptor Antagonists for Vasomotor Symptoms Application Introduction
  2. 5.1.1 Hospital and Clinic
  3. 5.1.2 Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application
  6. 5.2.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application (2021-2032)
  8. 5.2.3 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Application (2021-2032)
  9. 5.3 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Application
  10. 5.3.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Application (2021-2032)
  12. 5.3.3 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share by Application (2021-2032)
6 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Region
  1. 6.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Region (2021-2032)
  3. 6.2.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Region (2021-2026)
  4. 6.2.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Region
  1. 7.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Region
  2. 7.1.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Region (2021-2026)
  4. 7.1.3 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Region (2027-2032)
  5. 7.1.4 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue (2021-2032)
  8. 7.2.2 North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue (2021-2032)
  11. 7.3.2 Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Astellas Pharma
  2. 8.1.1 Astellas Pharma Company Information
  3. 8.1.2 Astellas Pharma Business Overview
  4. 8.1.3 Astellas Pharma Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Astellas Pharma Neurokinin Receptor Antagonists for Vasomotor Symptoms Product Portfolio
  6. 8.1.5 Astellas Pharma Recent Developments
  7. 8.2 Bayer
  8. 8.2.1 Bayer Company Information
  9. 8.2.2 Bayer Business Overview
  10. 8.2.3 Bayer Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Bayer Neurokinin Receptor Antagonists for Vasomotor Symptoms Product Portfolio
  12. 8.2.5 Bayer Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Neurokinin Receptor Antagonists for Vasomotor Symptoms Value Chain Analysis
  2. 9.1.1 Neurokinin Receptor Antagonists for Vasomotor Symptoms Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Neurokinin Receptor Antagonists for Vasomotor Symptoms Production Mode & Process
  6. 9.2 Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Neurokinin Receptor Antagonists for Vasomotor Symptoms Distributors
  9. 9.2.3 Neurokinin Receptor Antagonists for Vasomotor Symptoms Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst